Galcanezumab Boosts Brain Connectivity in Migraine Relief

Research Summary

A recent study published in Scientific Reports examines how the migraine treatment galcanezumab affects brain connectivity, offering insights into its long-term benefits. Researchers used electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) to analyze brain interactions in 15 migraine patients before, immediately after, and three months into treatment, with follow-ups after one year. Compared to 10 healthy controls, patients showed reduced brain network strength and clustering at all time points, but a significant increase in global efficiency by three months. This improved connectivity correlated with better clinical outcomes after one year, highlighting galcanezumab's potential in altering migraine-related brain function.

Study Details

📄 Title: Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome.

👥 Research Team: La Rocca M et al.

📚 Published In: Sci Rep

📅 Publication Date: 2025 Dec 10

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.